Precision Medicines for CNS and Rare Diseases

Small molecule therapeutics that boost cellular clearance pathways to restore balance
Our Science
Careers
Investors

PRECISION MEDICINES FOR CNS AND RARE DISEASES

Caraway Therapeutics is an emerging biopharmaceutical company pursuing novel approaches for the treatment of debilitating neurodegenerative and rare diseases diseases by enhancing cellular clearance. It is a leader in developing therapeutics that activate the lysosome, the cell’s recycling center, to clear toxic materials and defective cellular components.  Caraway has a rigorous, scientific product engine with multiple approaches, using genetically defined targets to find potential treatments related to these processes.

Urgent, Unmet Medical Need

Urgent, Unmet Medical Need

Targeted Approach

Targeted Approach

Leveraging Advances in Neuroscience

Leveraging Advances in Neuroscience

Addressing Rare Diseases

Addressing Rare Diseases

Neurodegenerative and rare diseases represent an urgent and expanding unmet medical need. Caraway’s approach to developing targeted treatments leverages the body’s natural ability to identify toxic cellular materials and enhances their clearance, preventing cell damage. By increasing lysosomal flux, Caraway’s small molecules can stimulate clearance of dysfunctional cellular components.

News

June 9, 2021
Caraway Therapeutics Establishes Collaboration with AbbVie to Develop Novel Small Molecule Therapeutics for Parkinson’s Disease and Other Related Disorders
June 9, 2021
Caraway Therapeutics Establishes Collaboration with AbbVie to Develop Novel Small Molecule Therapeutics for Parkinson’s Disease and Other Related Disorders

Our Team

Solutions to complex problems require an unique combination of rigor and creativity. The Caraway team drives our development programs forward by bringing passion and precision to our work every day.